Success Metrics

Clinical Success Rate
72.7%

Based on 8 completed trials

Completion Rate
73%(8/11)
Active Trials
0(0%)
Results Posted
113%(9 trials)
Terminated
3(25%)

Phase Distribution

Ph phase_3
1
8%
Ph phase_1
4
33%
Ph phase_2
7
58%

Phase Distribution

4

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
7(58.3%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

8 of 12 finished

Non-Completion Rate

33.3%

4 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(4)

Detailed Status

Completed8
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
72.7%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (33.3%)
Phase 27 (58.3%)
Phase 31 (8.3%)

Trials by Status

completed867%
terminated325%
withdrawn18%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_3

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453
completedphase_1

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

NCT01436656
completedphase_2

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

NCT01894672
completedphase_2

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

NCT02631447
completedphase_1

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

NCT01543698
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT01909453Phase 3

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

Completed
NCT01436656Phase 1

A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma

Completed
NCT01894672Phase 2

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Completed
NCT02631447Phase 2

Sequential Combo Immuno and Target Therapy (SECOMBIT) Study

Completed
NCT01543698Phase 1

A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Completed
NCT02159066Phase 2

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Completed
NCT01719380Phase 2

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Completed
NCT01981187Phase 2

LGX818 for Patients With BRAFV600 Mutated Tumors

Terminated
NCT02109653Phase 2

Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC

Withdrawn
NCT02278133Phase 1

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Completed
NCT01820364Phase 2

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma

Terminated
NCT01777776Phase 1

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Terminated

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12